Jazz Pharma to buy Celator Pharma for $1.5 billion and with it Vyxeos

Jazz Pharmaceuticals plc and Celator Pharmaceuticals, Inc. announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator for $30.25 per share in cash, or approximately $1.5 billion. The transaction with Celator is well-suited to advance Jazz Pharmaceuticals' growth strategy. �Vyxeos is the first product candidate to demonstrate a statistically significant improvement in Overall Survival in patients with high-risk (secondary) AML �FDA Breakthrough Therapy designation granted for Vyxeos. � FDA and European Commission Orphan Drug designation for Vyxeos for the treatment of AML � Vyxeos is an innovative product candidate based on the Celator CombiPlex platform